Drug Profile
Lamivudine/tenofovir disoproxil fumarate - Merck Sharp & Dohme
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Developer INSERM; UNITAID
- Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III HIV-1 infections
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for preclinical development in HIV-1-infections in Canada (PO, Granules)
- 12 Dec 2016 Chemical structure information added
- 28 Nov 2016 Merck Sharp & Dohme plans a phase I trial for HIV-1 infections (In volunteers) in Canada (PO) (EudraCT2016-004392-41)